Literature DB >> 2366126

True transposition procedures.

G R Diamond1.   

Abstract

Three patients with large-angle strabismus and irreversible amblyopia in a previously-operated eye underwent a true transposition procedure in which a segment of resected extraocular muscle was used to lengthen its antagonist. Postoperative results were satisfactory and stable during follow-up of 9 to 14 months. Four prism diopters of deviation were corrected per millimeter of "alteration" (mm resection plus mm lengthening plus mm recession minus mm advancement). True transposition procedures can permit surgeons to capture large strabismus deviations with two-muscle surgery on one eye, appear safe and predictable, and offer an option in those patients who refuse adjustable suture techniques.

Entities:  

Mesh:

Year:  1990        PMID: 2366126     DOI: 10.3928/0191-3913-19900501-12

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  4 in total

1.  Medial rectus muscle elongation, a technique to treat very large-angle esotropia.

Authors:  Ahmad Ameri; Mohammad Reza Akbari; Ali Reza Keshtkar Jaafari; Masoud Aghsaei Fard; Bahram Eshraghi; Vida Tavakoli; Arash Mirmohammadsadeghi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-07       Impact factor: 3.117

2.  Lateral Rectus Muscle Tendon Elongation by an Auto Graft from the Resected Medial Rectus Muscle as a Monocular Surgery for Large-Angle Sensory Exotropia.

Authors:  Heba M Shafik; Mohamed Ashraf Eldesouky; Dina Tadros
Journal:  Clin Ophthalmol       Date:  2020-07-24

3.  Loop myopexy with true muscle transplantation for very large angle heavy eye syndrome patient.

Authors:  Jitendra Jethani; Sonal Amin
Journal:  Indian J Ophthalmol       Date:  2015-01       Impact factor: 1.848

4.  Stability and effects of muscle transplantation for very large angle esotropia: A study of 22 patients.

Authors:  Jitendra Nenumal Jethani; Nirzari Shah; Sonal Amin; Monika Jethani
Journal:  Indian J Ophthalmol       Date:  2017-07       Impact factor: 1.848

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.